A Strategy for Iron Refractory Anemia by Rikkunshi-to / 日本東洋医学雑誌

ABSTRACT

During the administration of Rikkunshi-to, hematological findings and complications of underlying disease were examined in patients with refractory anemia treated with oral iron preparations. In all 11 evaluative cases, hemoglobin levels before the administration of Rikkunshi-to were 10.7±0.8g/dL, and 11.5±0.8g/dL post-administration (mean administration period 17.3±11.6 months), indicating a significant hemoglobin level increase. In 9 out of 11 cases (82%), an improvement in anemia was observed. Eight out of 11 cases (73%) had atrophic gastritis, reflux esophagitis, or other gastrointestinal disease complications. Rikkunshi-to is considered to be effective such factors as an improvement in hematopoiesis through a promotion of DNA synthesis in bone marrow cells with prostisol; and an improvement in iron absorption and utilization with improving appetite, although, the exact mechanisms have yet to be elucidated.<br>In conclusion, Rikkunshi-to can be considered an appropriate medication for the improvement of refractory anemia treated with the administration of oral iron preparations. However, its mechanism of action, as well as its recommended administration for specific disease states remain important issues for the future.